|
1
|
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.
|
Blood
|
2007
|
5.18
|
|
2
|
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
|
J Clin Oncol
|
2005
|
3.61
|
|
3
|
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
|
Blood
|
2004
|
3.04
|
|
4
|
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).
|
Blood
|
2006
|
2.83
|
|
5
|
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
|
Blood
|
2009
|
2.09
|
|
6
|
Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system.
|
J Clin Oncol
|
2011
|
1.90
|
|
7
|
Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
|
J Clin Oncol
|
2007
|
1.67
|
|
8
|
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.
|
J Clin Oncol
|
2013
|
1.46
|
|
9
|
Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years.
|
Haematologica
|
2002
|
1.42
|
|
10
|
Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.
|
Blood
|
2004
|
1.41
|
|
11
|
A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial.
|
Blood
|
2010
|
1.41
|
|
12
|
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
|
Cancer
|
2006
|
1.17
|
|
13
|
Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation.
|
Blood
|
2004
|
1.03
|
|
14
|
Prophylactic platelet transfusion.
|
N Engl J Med
|
2013
|
1.00
|
|
15
|
Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study.
|
J Clin Oncol
|
2011
|
0.92
|
|
16
|
Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.
|
J Clin Oncol
|
2010
|
0.87
|
|
17
|
An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
|
J Antimicrob Chemother
|
2005
|
0.87
|
|
18
|
Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
|
Eur J Haematol
|
2006
|
0.86
|
|
19
|
Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy.
|
Onkologie
|
2007
|
0.83
|
|
20
|
Two allogeneic hematopoietic stem cell transplantations without the use of blood-product support.
|
Haematologica
|
2005
|
0.83
|
|
21
|
FDG PET for imaging pericardial manifestations of Hodgkin lymphoma.
|
Clin Nucl Med
|
2003
|
0.80
|
|
22
|
Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myeloma.
|
Biol Blood Marrow Transplant
|
2010
|
0.77
|
|
23
|
WHO classification of myeloid neoplasms and leukemia.
|
Blood
|
2010
|
0.76
|
|
24
|
Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
|
Bone Marrow Transplant
|
2003
|
0.75
|
|
25
|
In Reply.
|
Dtsch Arztebl Int
|
2015
|
0.75
|
|
26
|
Therapeutic platelet transfusion for hypoproliferative thrombocytopenia - authors' reply.
|
Lancet
|
2013
|
0.75
|
|
27
|
Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma.
|
Leuk Lymphoma
|
2014
|
0.75
|
|
28
|
Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy.
|
Blood
|
2010
|
0.75
|